Mga Batayang Estadistika
| LEI | 549300GZXI59U71XPM70 |
| CIK | 1410939 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IVERIC bio Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2024 |
ISEE / IVERIC bio Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36080 IVERIC bio, Inc. (Exact name of registrant as specified in its cha |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
Registration No. 333-253897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-253897 UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or jurisdiction of incorporation or organization) 20-8185347 (I.R.S. Employer Identification Numbe |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IVERIC BIO, INC. a Delaware corporation (hereinafter called the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. Other Offices. The Corporation may also have offices at such other places both within and without the |
|
| July 11, 2023 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION FIRST The name of the corporation is IVERIC bio, Inc. (the “Company”). SECOND The Company’s registered office in the State of Delaware is located at 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808. Its registered agent at such address is Corporation Service Company. THIRD The p |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 11, 2023 |
Registration No. 333-260406 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-260406 UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or jurisdiction of incorporation or organization) 20-8185347 (I.R.S. Employer Identification Numbe |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 11, 2023 |
As filed with the Securities and Exchange Commission on July 11, 2023 As filed with the Securities and Exchange Commission on July 11, 2023 Registration No. |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2023 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 29, 2023 |
Exhibit 99.1 ISEE Transaction Employee Q&A 1. For the acquisition of Iveric Bio, would it be possible to describe all major milestones, after the stockholder meeting, until the end of the transaction, so we know where we are in the process? a. Given that the HSR waiting period has now expired, following the stockholder meeting scheduled for July 6th – provided that the merger will be approved by t |
|
| June 26, 2023 |
CONFIDENTIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definiti |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 5, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| June 1, 2023 |
Exhibit 99.1 ISEE Transaction Employee Q&A 1. Can you go into more detail on how our corporate goals will change with the acquisition? I know the FAQs say “business as usual” but it doesn’t seem like that. Will the pipeline, finance, legal and HR/comms goals get changed soon or by Astellas? a. See FAQ #20 in the Employee FAQs distributed to Iveric’s employees on April 30, 2023, which is available |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 24, 2023 |
Exhibit 99.1 ISEE Investor FAQs 1. We saw in the preliminary proxy statement that the deadline to file the notification and report form under the HSR Act regarding the transaction with Astellas is today. Has Iveric Bio made its HSR filing? · Yes. We and Astellas each filed a notification and report form with the Department of Justice and the Federal Trade Commission under the HSR Act on May 24, 20 |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 23, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) IVERIC bio, Inc. |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 19, 2023 |
Exhibit 99.1 ISEE Transaction Employee Q&A 1. How will I receive payment under the merger agreement with respect to shares I own outright and my stock options and time-vesting restricted stock unit awards? · Payments with respect to shares that are owned outright will be made by a third party paying agent engaged by Astellas. If you hold shares outright, shortly after closing you will receive inst |
|
| May 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IVERIC bio, Inc. |
|
| May 17, 2023 |
As filed with the Securities and Exchange Commission on May 17, 2023 S-8 1 tm2315986d1s8.htm S-8 As filed with the Securities and Exchange Commission on May 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-8185347 (State or Other Jurisdiction of Incorporation or Org |
|
| May 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 10, 2023 |
to 2019 Inducement Plan of the Registrant, dated February 23, 2023 Amendment No. 6 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 6 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the |
|
| May 10, 2023 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| May 10, 2023 |
AMENDMENT NO. 5 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY OF IVERIC BIO, INC. The Non-Employee Director Compensation Policy (the “Policy”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Policy): 1. The section in the Policy captioned “Equity Compensation” under |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 3, 2023 |
ISEE Transaction Social Media Employee Communication Exhibit 99.1 ISEE Transaction Social Media Employee Communication Subject: Reminder: Do NOT Discuss or Post About the Astellas Transaction on Social Media Team, As we work towards completing our transaction with Astellas, we’d like to remind you that it is imperative that you do not discuss or post about the transaction in any way on social media. This includes making, sharing, liking or commentin |
|
| May 1, 2023 |
Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Iveric Bio -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas’ Primary Focus on “Blindness & Regeneration”- -Acquisition price of US$40 per share in cash, repre |
|
| May 1, 2023 |
Amendment to IVERIC bio, Inc.’s Amended and Restated Bylaws, dated April 28, 2023 Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BY-LAWS OF IVERIC BIO, INC. ARTICLE V GENERAL PROVISIONS 5.9 Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding br |
|
| May 1, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: IVERIC bio, Inc., a Delaware corporation; Astellas US Holding, Inc., a Delaware corporation; Berry Merger Sub, Inc., a Delaware corporation; and solely as provided by Section 8.10(b) of this Agreement, Astellas Pharma Inc., a company organized under the laws of Japan Dated as of April 28, 2023 Table of Contents Section 1 MERGER TRA |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 1, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: IVERIC bio, Inc., a Delaware corporation; Astellas US Holding, Inc., a Delaware corporation; Berry Merger Sub, Inc., a Delaware corporation; and solely as provided by Section 8.10(b) of this Agreement, Astellas Pharma Inc., a company organized under the laws of Japan Dated as of April 28, 2023 Table of Contents Section 1 MERGER TRA |
|
| May 1, 2023 |
Joint Press Release issued by IVERIC bio, Inc. and Astellas Pharma Inc. on April 30, 2023 Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Iveric Bio -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas’ Primary Focus on “Blindness & Regeneration”- -Acquisition price of US$40 per share in cash, repre |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2023 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 1, 2023 |
Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BY-LAWS OF IVERIC BIO, INC. ARTICLE V GENERAL PROVISIONS 5.9 Forum for Adjudication of Certain Disputes. Unless the corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding br |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2023 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of |
|
| March 20, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 1, 2023 |
TABLE OF CONTENTS PART IV INDEX TO FINANCIAL STATEMENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 1, 2023 |
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results -FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 - -Post-hoc Time-to-Event Analysis of ACP GATHER Trials Signals up to 59% Risk Reduction in Rate of Vision Loss Compared to Sham at 12 Months – -Commercial Launch Preparations for ACP Continue to Accelerate – - Conference Call and Webcast Today, March 1, 2023, at 8:00 a. |
|
| March 1, 2023 |
Exhibit 21.1 Subsidiaries of IVERIC bio, Inc. IVERIC bio Gene Therapy LLC, a Delaware limited liability company Orion Ophthalmology LLC, a Delaware limited liability company IVERIC bio Europe Limited, an Irish Registered Company |
|
| March 1, 2023 |
Amendment No. 1 to 2016 Employee Stock Purchase Plan AMENDMENT NO. 1 TO 2016 EMPLOYEE STOCK PURCHASE PLAN OF IVERIC BIO, INC. The 2016 Employee Stock Purchase Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1.Section 3 of the Plan be and hereby is deleted in its entirety and the following is in |
|
| March 1, 2023 |
Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| March 1, 2023 |
Amendment No. 6 to 2019 Inducement Plan of the Registrant Amendment No. 6 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 6 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the |
|
| March 1, 2023 |
Amendment No. 6 to 2019 Inducement Stock Incentive Plan Exhibit 99.9 Amendment No. 6 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 6 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4( |
|
| March 1, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IVERIC bio, Inc. |
|
| March 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 S-8 1 tm238157d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organ |
|
| March 1, 2023 |
EXECUTION VERSION CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-isee123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / RTW INVESTMENTS, LP - IVERIC BIO, INC. Passive Investment SC 13G/A 1 p23-0638sc13ga.htm IVERIC BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IVERIC bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appr |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / Vivo Capital IX, LLC - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P 102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994205213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2023 |
ISEE / IVERIC bio Inc / Avoro Capital Advisors LLC - IVERIC BIO, INC. Passive Investment SC 13G/A 1 p23-0572sc13ga.htm IVERIC BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IVERIC bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appr |
|
| February 10, 2023 |
ISEE / IVERIC bio Inc / Flynn James E Passive Investment SC 13G/A 1 e618242sc13ga-iveric.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * IVERIC bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 202 |
|
| February 9, 2023 |
ISEE / IVERIC bio Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01197-ivericbioinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: IVERIC bio Inc. Title of Class of Securities: Common Stock CUSIP Number: 46583P102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which th |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 5, 2022 |
EX-1.1 2 tm2231850d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version 13,350,000 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT November 30, 2022 November 30, 2022 Morgan Stanley & Co. LLC BofA Securities, Inc. Cowen and Company, LLC as Representatives of the several Underwriters listed in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New Y |
|
| December 5, 2022 |
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock Exhibit 99.1 Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock PARSIPPANY, N.J., November 30, 2022 ? IVERIC bio, Inc. (Nasdaq: ISEE) (the ?Company?), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition, in conn |
|
| December 5, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
13,350,000 Shares of Common Stock 424B5 1 tm2231050-3424b5.htm 424B5 TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-260406 PROSPECTUS SUPPLEMENT To Prospectus Dated October 21, 2021 13,350,000 Shares of Common Stock We are offering 13,350,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “ISEE”. On November 30, 2022, the last reported sale p |
|
| December 1, 2022 |
EX-FILING FEES 2 tm2231050d4ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| November 30, 2022 |
$250,000,000 Shares of Common Stock 424B5 1 tm2231050-1424b5.htm 424B5 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we a |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2022 |
Proposed Settlement of Shareholder Derivative Action, dated January 20, 2023 1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LUIS PACHECO, Derivatively on Behalf of OPHTHOTECH CORPORATION, Plaintiff, v. |
|
| November 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 4, 2022 |
Stipulation of Settlement and Notice of Pendency, dated January 20, 2023 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK LUIS PACHECO, Derivatively on Behalf of OPHTHOTECH CORPORATION, Plaintiff, v. |
|
| November 4, 2022 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| November 3, 2022 |
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results -Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - -Planned NDA Submission Moved Up to End of This Year ? -Received Favorable Feedback from FDA on Intermediate AMD Development Plan - - Conference Call and Webcast Today, November 3, 2022, at 8:00 a. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 4, 2022 |
ISEE / IVERIC bio Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| September 28, 2022 |
1 AVACINCAPTAD PEGOL IN GEOGRAPHIC ATROPHY DHAVAL DESAI SVP & CHIEF DEVELOPMENT OFFICER Avacincaptad Pegol is an investigational product that has not been evaluated for safety and efficacy by the FDA FORWARD-LOOKING STATEMENTS Any statements in this presentation about IVERIC bio (the Company)?s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 16, 2022 |
ISEE / IVERIC bio Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy -Primary Endpoint Met with 14. |
|
| July 26, 2022 |
Exclusive License Agreement between the Registrant and DelSiTech Ltd., dated June 30, 2022 EXECUTION VERSION CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| July 26, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 26, 2022 |
Amendment No. 5 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 5 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the ?Plan?) of IVERIC bio, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 26, 2022 |
Amendment No. 5 to the 2019 Inducement Stock Incentive Plan Exhibit 99.6 Amendment No. 5 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 5 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the ?Plan?) of IVERIC bio, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4( |
|
| July 26, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IVERIC bio, Inc. |
|
| July 26, 2022 |
, and the several banks and other financial institutions or entities from time to time parties Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| July 26, 2022 |
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results -Zimura? GATHER2 Topline Data Expected in September of this Year- -GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92. |
|
| July 26, 2022 |
As filed with the Securities and Exchange Commission on July 26, 2022 As filed with the Securities and Exchange Commission on July 26, 2022 Registration No. |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 5, 2022 |
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura® Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura? Parsippany, N. |
|
| May 18, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 4, 2022 |
Amendment No. 4 to Non-Employee Director Compensation Policy AMENDMENT NO. 4 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY? OF IVERIC BIO, INC. The Non-Employee Director Compensation Policy (the ?Policy?) of IVERIC bio, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Policy): 1.? The section in the Policy captioned ?Equity Compensation? under |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 4, 2022 |
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results ?Zimura? GATHER2 Topline Data Expected in the Third Quarter of this Year- ?GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90% ? ?U. |
|
| May 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 24, 2022 |
Letter Agreement between the Registrant and Tony Gibney dated November 10, 2021 Mr. Anthony Gibney c/o IVERIC bio, Inc. Five Penn Plaza, Suite 2372 New York, NY 10001 Dear Tony: The board of directors of IVERIC bio, Inc. (the ?Company?) has provided for the following severance benefits to be provided to you in the event of your termination of employment with the Company, on the terms and conditions set forth herein. 1. Severance. (a) Subject to Section 1(b), |
|
| February 24, 2022 |
S-8 1 tm227508d2s8.htm FORM S-8 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or O |
|
| February 24, 2022 |
Amendment No. 4 to the 2019 Inducement Stock Incentive Plan Exhibit 99.7 Amendment No. 4 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 4 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the ?Plan?) of IVERIC bio, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4( |
|
| February 24, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IVERIC bio, Inc. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 24, 2022 |
TABLE OF CONTENTS PART IV INDEX TO FINANCIAL STATEMENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Amendment No. 4 to 2019 Inducement Stock Incentive Plan AMENDMENT NO. 4 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the ?Plan?) of IVERIC bio, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the |
|
| February 24, 2022 |
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results ?Zimura? GATHER2 Topline Data Expected in the Second Half of 2022 - ?GATHER2 Trial Completion at 84% for Year One; Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate Target Greater than 90% ? ?Internal Efforts for Preparation of a New Drug Application (NDA) Ongoing - ?Zimura Phase 3 Clinical Trial for Intermediate AMD to Initiate in Second Half of 2022 ? - Conference Call and Webcast Today, February 24, 2022, at 8:00 a. |
|
| February 24, 2022 |
Letter Agreement between the Registrant and Christopher Simms dated June 16, 2021 June 16, 2021 Mr. Christopher Simms c/o IVERIC bio, Inc. 5 Penn Plaza, Suite 2372 New York, NY 10001 Dear Chris: IVERIC bio, Inc. (the ?Company?) will provide for the following severance benefits for you in the event of your termination of employment with the Company, on the terms and conditions set forth herein. 1. Severance. (a) Subject to Section 1(b), if your employment is terminated (1) at an |
|
| February 24, 2022 |
Offer Letter between the Registrant and Christopher Simms dated June 16, 2021 June 16, 2021 [**] Dear Chris: On behalf of IVERIC bio, Inc. (the ?Company?) it is my pleasure to extend to you this offer of employment with the Company for the position of Senior Vice President & Chief Commercial Officer, reporting to Glenn Sblendorio, Chief Executive Officer. The terms of this offer, which are contingent on you and us determining a mutually agreed upon start date (the ?Start Da |
|
| February 24, 2022 |
Offer Letter between the Registrant and Tony Gibney dated Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| February 24, 2022 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| February 24, 2022 |
Exhibit 21.1 Subsidiaries of IVERIC bio, Inc. IVERIC bio Gene Therapy LLC, a Delaware limited liability company Orion Ophthalmology LLC, a Delaware limited liability company |
|
| February 15, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 15, 2022 |
ISEE / IVERIC bio Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P 102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
ISEE / IVERIC bio Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
ISEE / IVERIC bio Inc / Vivo Capital IX, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 11, 2022 |
ISEE / IVERIC bio Inc / Flynn James E Passive Investment SC 13G/A 1 e621297sc13ga-iveric.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * IVERIC bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 202 |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 11, 2022 |
AMENDMENT NO. 3 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY IVERIC BIO, INC. AMENDMENT NO. 3 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY OF IVERIC BIO, INC. The Non-Employee Director Compensation Policy (the “Policy”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Policy): 1. The section in the Policy captioned “General Compensation Limit |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 9, 2021 |
Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results ?Zimura? GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% - - Preparations of a New Drug Application (NDA) and Building Commercial Infrastructure are Underway for a Potential Launch of Zimura for the Treatment of Geographic Atrophy Secondary to Ag |
|
| November 9, 2021 |
Form S-8, File No. 333-260917, filed with the Securities and Exchange Commission on November 9, 2021 S-8 1 tm2132353d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IVERIC bio, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-8185347 (State or Other Jurisdiction of Incorporation |
|
| November 9, 2021 |
EX-10.4 5 isee9302021exhibit104.htm EX-10.4 November 3, 2021 Mr. Glenn Sblendorio Dear Glenn: The board of directors (the “Board”) of IVERIC bio, Inc. (the “Company”) has provided for the following severance benefits to be provided to you in the event of your termination of employment with the Company, on the terms and conditions set forth herein. This letter agreement dated as of the date first s |
|
| November 9, 2021 |
EX-10.3 4 isee9302021exhibit103.htm EX-10.3 AMENDMENT NO. 3 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and |
|
| November 9, 2021 |
Letter Agreement between the Registrant and Christopher Simms, dated June 16, 2021 June 16, 2021 Mr. Christopher Simms c/o IVERIC bio, Inc. 5 Penn Plaza, Suite 2372 New York, NY 10001 Dear Chris: IVERIC bio, Inc. (the ?Company?) will provide for the following severance benefits for you in the event of your termination of employment with the Company, on the terms and conditions set forth herein. 1. Severance. (a) Subject to Section 1(b), if your employment is terminated (1) at an |
|
| November 9, 2021 |
Offer of Employment between the Registrant and Christopher Simms, dated June 16, 2021 June 16, 2021 Mr. Christopher Simms 1 Beverly Road Madison, NJ 07940 Dear Chris: On behalf of IVERIC bio, Inc. (the ?Company?) it is my pleasure to extend to you this offer of employment with the Company for the position of Senior Vice President & Chief Commercial Officer, reporting to Glenn Sblendorio, Chief Executive Officer. The terms of this offer, which are contingent on you and us determinin |
|
| November 9, 2021 |
Amendment No. 3 to 2019 Inducement Stock Incentive Plan EX-99.4 4 tm2132353d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 AMENDMENT NO. 3 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of th |
|
| October 25, 2021 |
ISEE / IVERIC bio Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 25, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File |
|
| October 25, 2021 |
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.1 Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock NEW YORK, NY, October 21, 2021 ? IVERIC bio, Inc. (Nasdaq: ISEE) (the ?Company?), today announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions. In addition, in connection with |
|
| October 25, 2021 |
EX-1.1 2 tm2130533d6ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version | October 21, 2021 9,000,000 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT October 21, 2021 October 21, 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters listed |
|
| October 22, 2021 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS CALCULATION OF REGISTRATION FEE ? ? Title of each class of securities to be registered ? ? ? Amount to be registered(1) ? ? ? Proposed maximum offering price per unit ? ? ? Proposed maximum aggregate offering price(1) ? ? ? Amount of registration fee(2) ? Common Stock, par value $0. |
|
| October 21, 2021 |
Form of Subordinated Indenture Exhibit 4.4 IVERIC BIO, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapp |
|
| October 21, 2021 |
$125,000,000 Shares of Common Stock TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| October 21, 2021 |
EX-99.1 2 october20218-kriskfactors.htm EX-99.1 Exhibit 99.1 Risk Factors The following risk factors should be carefully considered together with all of the other information in our annual and quarterly reports and other filings with the U.S. Securities and Exchange Commission, or the SEC. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risk |
|
| October 21, 2021 |
EX-4.5 4 tm2130533d3ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY T |
|
| October 21, 2021 |
EX-4.3 2 tm2130533d3ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 IVERIC BIO, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 3 |
|
| October 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 21, 2021 |
EX-4.6 5 tm2130533d3ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSI |
|
| October 21, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 21, 2021 Registration No. |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 4, 2021 |
EX-99.1 2 isee2qearningspressrelease.htm EX-99.1 Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results –FDA Agreement Under Special Protocol Assessment (SPA) Received for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration – –Zimura GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection F |
|
| August 4, 2021 |
AMENDMENT NO. 2 TO MASTER SPONSORED RESEARCH AGREEMENT This Amendment No. 2 to the Master Sponsored Research Agreement (?Amendment No. 2?) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (?Penn?), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104-4310, and IVERIC bio Gene Therapy LLC (s |
|
| August 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 14, 2021 |
Exhibit 1.1 Execution Version | July 12, 2021 11,650,000 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT July 12, 2021 July 12, 2021 Cowen and Company, LLC Credit Suisse Securities (USA) LLC Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters listed in Schedule I hereto c/o Cowen and Company, LLC 599 Lexington Avenue New Y |
|
| July 14, 2021 |
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock EX-99.1 4 tm2022716d6ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock NEW YORK, NY, July 12, 2021 – IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and |
|
| July 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 14, 2021 |
11,650,000 Shares of Common Stock TABLE OF CONTENTS ?As Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-253897? PROSPECTUS SUPPLEMENT To Prospectus Dated April 9, 2021 11,650,000 Shares of Common Stock We are offering 11,650,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?ISEE?. On July 12, 2021, the last reported sale price of our common stock on The Nasdaq G |
|
| July 12, 2021 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 21, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 5, 2021 |
EX-10.2 2 exhibit102-amendmentno2ton.htm EX-10.2 AMENDMENT NO. 2 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY OF IVERIC BIO, INC. The Non-Employee Director Compensation Policy (the “Policy”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Policy): 1. The section in t |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 5, 2021 |
Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results ?GATHER2 On-Track to Complete Enrollment in 3Q of this Year - - Conference Call and Webcast Today, May 5, 2021, at 8:00 a. |
|
| May 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 9, 2021 |
$100,000,000 IVERIC bio, Inc. Common Stock Filed Pursuant to Rule 424(b)(1) Registration No. 333-253897 $100,000,000 PROSPECTUS IVERIC bio, Inc. Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) x Defin |
|
| April 7, 2021 |
As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. |
|
| April 7, 2021 |
CORRESP 1 filename1.htm April 7, 2021 VIA EDGAR SUBMISSION Margaret Schwartz Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: IVERIC bio, Inc. Registration Statement on Form S-3 File No. 333-253897 Request for Acceleration Dear Ms. Schwartz: Pursuant to Rule 461 under the Securities Act of 1933, as amended, IVERIC bio, Inc. hereby request |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) o Defin |
|
| April 5, 2021 |
David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund EX-99.1 3 tm2112090d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund New York, NY— April 5, 2021 —– IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting sc |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 5, 2021 |
EX-10.1 2 tm2112090d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 RETIREMENT AND CONSULTING AGREEMENT This RETIREMENT AND CONSULTING AGREEMENT (this “Agreement”) is made and dated as of April 4, 2021, by and between IVERIC bio, Inc. (the “Company”) and David R. Guyer, M.D. (the “Executive”). WHEREAS, the Executive is employed as Executive Chairman of the Company pursuant to an employment letter, dated Apr |
|
| March 5, 2021 |
Sales Agreement, dated as of March 4, 2021, by and among the Registrant and Cowen and Company, LLC EX-1.2 2 tm218372d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 IVERIC BIO, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Iveric bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Co |
|
| March 5, 2021 |
EX-4.3 3 tm218372d2ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 IVERIC BIO, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 |
|
| March 5, 2021 |
EX-4.5 5 tm218372d2ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO |
|
| March 5, 2021 |
Form S-8, File No. 333-253896, filed with the Securities and Exchange Commission on March 5, 2021 ? As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 5, 2021 |
Amendment No. 2 to 2019 Inducement Stock Incentive Plan EX-99.5 4 tm218379d2ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 AMENDMENT NO. 2 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the |
|
| March 5, 2021 |
EX-4.6 6 tm218372d2ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSIT |
|
| March 5, 2021 |
Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on March 5, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 5, 2021 |
Form of Subordinated Indenture Exhibit 4.4 IVERIC BIO, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| March 4, 2021 |
TABLE OF CONTENTS PART IV INDEX TO FINANCIAL STATEMENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 4, 2021 |
EX-10.12 3 isee12312020exhibit1012.htm EX-10.12 Exhibit 10.12 AMENDMENT NO. 2 TO 2019 INDUCEMENT STOCK INCENTIVE PLAN OF IVERIC BIO, INC. The 2019 Inducement Stock Incentive Plan (the “Plan”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) o |
|
| March 4, 2021 |
EX-21.1 4 isee12312020ex211subsidiar.htm EX-21.1 Exhibit 21.1 Subsidiaries of IVERIC bio, Inc. IVERIC bio Gene Therapy LLC, a Delaware limited liability company Orion Ophthalmology LLC, a Delaware limited liability company |
|
| March 4, 2021 |
EX-3.1 2 isee12312020exhibit31.htm EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF OPHTHOTECH CORPORATION (originally incorporated on January 5, 2007) Ophthotech Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A. The current name of the Co |
|
| March 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 3, 2021 |
EX-99.1 2 iseeyearendearningspressre.htm EX-99.1 Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results - Patient Enrollment for GATHER2 Clinical Trial of Zimura® for the Treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration Ahead of Target and Progressing Well; Completion of Enrollment Expected in 3Q of this Year - - Conference Cal |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IVERIC BIO INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 16, 2021 |
EX-1 2 d117432dex1.htm EX-1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date:February 16, 2021 PERCE |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IVERIC BIO INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IVERIC bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46583P102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 1 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of IVERIC bio, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto furth |
|
| February 10, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* IVERIC bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) Calendar Year 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 11, 2021 |
Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 3, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 2, 2020 |
IVERIC bio Reports Third Quarter 2020 Operational Highlights and Financial Results - Conference Call and Webcast Today, November 2, 2020, at 8:00 a. |
|
| October 28, 2020 |
ISEE / IVERIC bio, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 46583P 102 (CUSIP Number) October 22, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| October 28, 2020 |
EX-99.1 2 d41235dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 28, 202 |
|
| September 18, 2020 |
As filed with the Securities and Exchange Commission on September 18, 2020 Registration No. |
|
| August 14, 2020 |
IVERIC bio, Inc. 8,649,453 Shares of Common Stock 424B3 1 tm2026163-4424b3seq1.htm 424B3 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-241714 PROSPECTUS IVERIC bio, Inc. 8,649,453 Shares of Common Stock This prospectus relates to resales of shares of common stock previously issued by IVERIC bio, Inc. to the selling stockholders identified in this prospectus on June 22, 2020, in a private placement. We will not receive |
|
| August 11, 2020 |
August 11, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: IVERIC bio, Inc. |
|
| August 6, 2020 |
pdugelseveranceagreement March 11, 2020 Dr. Pravin Dugel c/o IVERIC bio, Inc. One Penn Plaza, Suite 3520 New York, NY 10119 Dear Pravin The board of directors (the “Board”) of IVERIC bio, Inc. (the “Company”) has provided for the following severance benefits to be provided to you in the event of your termination of employment with the Company, on the terms and conditions set forth herein. 1. Sever |
|
| August 6, 2020 |
pdugelofferv2 One Penn Plaza, 35th Floor, New York, NY 10119 Phone: 212-845-8200 Fax: 212-845-8250 March 11, 2020 Dr. |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 6, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 6, 2020 Registration No. |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 5, 2020 |
IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results - Conference Call and Webcast Today, August 5, 2020, at 8:00 a. |
|
| July 17, 2020 |
amendmentno1tonedcp AMENDMENT NO. 1 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY OF IVERIC BIO, INC. The Non-Employee Director Compensation Policy (the “Policy”) of IVERIC bio, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Policy): 1. The section in the Policy captioned “Equity C |
|
| July 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2020 IVERIC bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36080 20-8185347 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 1, 2020 |
ISEE / IVERIC bio, Inc. / Flynn James E Passive Investment SC 13G 1 e619739sc13g-iveric.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * IVERIC bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) June 22, 2020 (Date |
|
| June 29, 2020 |
ISEE / IVERIC bio, Inc. / RTW INVESTMENTS, LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* IVERIC bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) June 19, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| June 29, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of IVERIC bio, Inc. |
|
| June 26, 2020 |
ISEE / IVERIC bio, Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IVERIC bio, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46583P102 (CUSIP Number) June 22, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| June 24, 2020 |
ISEE / IVERIC bio, Inc. / Versant Side Fund IV, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) IVERIC BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46583P102 (CUSIP Number) June 19, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| June 19, 2020 |
Exhibit 4.1 EXHIBIT A IVERIC bio, Inc. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: June [ ], 2020 IVERIC bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder |
|
| June 19, 2020 |
Exhibit 1.1 Execution Version 24,535,720 Shares Pre-Funded Warrants to Purchase 1,914,280 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT June 17, 2020 June 17, 2020 Cowen and Company, LLC Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters listed in Schedule I hereto c/o Cowen and Company, LLC 599 Lexington Avenue New York, New |
|
| June 19, 2020 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of June 17, 2020, by and between IVERIC bio, Inc., a Delaware corporation (the “Company”), and the Persons set forth on Schedule 1 of this Agreement (together with their successors and assigns, the “Purchasers” and, together with the Company, the “Parties”). W I T N E S S E T H: WHEREAS, the Company |
|
| June 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 IVERIC bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36080 20-8185347 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 19, 2020 |
PROSPECTUS SUPPLEMENT To Prospectus Dated August 15, 2018 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| June 19, 2020 |
Exhibit 99.1 IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants NEW YORK, NY, June 18, 2020 – IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 24,535,720 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock |
|
| June 17, 2020 |
PROSPECTUS SUPPLEMENT (Subject to Completion) Dated June 17, 2020 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. |
